%0 Journal Article
%T Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
%A Michael C Mosier
%A Rudolph M Navari
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S201609
%X Introduction: HTX-019 (CINVANTI£¿) is a novel injectable emulsion formulation of the neurokinin 1 receptor antagonist (RA) aprepitant, approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 has demonstrated a tolerable safety profile when administered via 30-min intravenous (IV) infusion and 2-min IV injection in healthy volunteers. This prospective study evaluated the safety of HTX-019 administered via 30-min IV infusion and 2-min injection (IV push) in patients with cancer
%K aprepitant
%K bag shortage
%K CINV
%K HTX-019
%K real world
%K short injection
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503333/